Articles
Optimal Clinical Trials, a leading Phase 1b-3 research centre in the Asia-Pacific region, is proud to celebrate the recent milestone FDA approval of Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults.
This groundbreaking approval will enable adults aged 60 years and older to be protected from RSV disease for the first time, providing them with a better quality of life.
The newly approved Arexvy vaccine marks the culmination of a long-standing scientific effort to combat the significant burden of RSV disease, especially among older adults with underlying medical conditions such as heart disease, diabetes, and lung disease. RSV is a contagious virus that causes respiratory illnesses and has been responsible for causing a large number of hospitalisations and deaths among older adults each year. This groundbreaking vaccine, with its exceptional efficacy in this vulnerable population, has the potential to positively impact public health and improve the quality of life of older adults.
As a clinical research site for Arexvy, Optimal Clinical Trials played a significant role in the successful FDA approval of this vaccine. Our expert investigator doctors and specialists worked closely with GSK and PPD to provide exceptional care to our patients, ensuring quality data collection and patient safety.
"We are privileged to have worked with GSK on this project and are thrilled to celebrate this remarkable milestone in the fight against RSV. This achievement reflects the dedication and hard work of everyone involved in this trial, and we are proud to have contributed to the development of this vaccine that will have a significant positive public health impact."
Dr Tori Middlemiss, Lead Research Physician & Principal Investigator, Optimal Clinical Trials
This approval is not only a significant achievement for GSK but also a testament to the power of collaboration and the potential of medical research to transform lives. We are honoured to have been a part of this journey and are excited to see the positive impact this vaccine will have on people's lives.
At Optimal Clinical Trials, we are dedicated to compassionate and effective research that inspires hope and improves lives. We look forward to aiding medical discoveries going forward and are committed to continuing our partnership with GSK, PPD, and other leading pharmaceutical companies in the development of innovative treatments that can benefit people worldwide.
About Optimal Clinical Trials
At Optimal Clinical Trials, we believe in the power of research to transform lives and make a positive impact. Our values of putting people first, integrity, partnership, creating value through high performance, continuous improvement, and knowing that time is of the essence underpin everything we do.
A leading outpatient Phase 1b-3 research centre in Asia-Pacific based in New Zealand, we specialise in commercial trials across various therapeutic areas. A multi-awarded Deloitte Fast 50 company, we take pride in our ISO 9001 quality certification.
Our passion and commitment set us apart – inspiring hope and supporting discoveries that can improve people’s lives.
For more information, please get in touch via our Research Enquiries form.